CanWell Advances First HER2-Targeting, Dual Cytotoxic Payload ADC Into Phase I

 
• By Dexter Jie Yan
  
twin flower 2
CanWell's approach to dual-payload-linker design is branched (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip